Brief: Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis
02/06/2025 13:22
June 2 (Reuters) - Aclaris Therapeutics Inc ACRS.O: ACLARIS THERAPEUTICS INITIATES PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNX87W0hg Further company coverage: ACRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Aclaris Therapeutics Q3 revenue beats analyst estimates
Brief: Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 Million
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aclaris Therapeutics Q2 revenue beats analyst estimates